Mr. Jerry Williamson

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 8/30/2007    Last Visited: 9/6/2007  

  collaboration programs in genomics at Affymetrix," said Jerry Williamson, Executive Vice President and Chief Commercial Officer at VisEn."His

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 6/19/2007    Last Visited: 7/3/2007  

  VisEn Medical Announces Jerry Williamson as Executive Vice President and Chief Commercial OfficerVisEn Medical Announces Jerry Williamson as Executive Vice President and Chief Commercial Officer
  ...
  VisEn Medical Announces Jerry Williamson as Executive Vice President and Chief Commercial Officer
  ...
  announced that Jerry Williamson will join the Company as Executive Vice President and Chief Commercial Officer.In this new position for the Company, Mr. Williamson will lead VisEn's worldwide Sales, Marketing, Manufacturing and Customer Support Programs.Mr. Williamson's role with VisEn is a key component in furthering the Company's mission of providing today's leading research, pharmaceutical and clinical institutions with the top technologies and solutions in translational fluorescence molecular imaging. Jerry Williamson has most recently served as President of Biacore, Inc., a leading provider of life science analytical products (acquired by GE Healthcare in 2006).Prior to working with Biacore, Mr. Williamson was President of the genetic detection company, Pyrosequencing, Inc.Mr. Williamson has over 20 years of senior management and strategic and tactical business experience in life science, pharmaceutical and biotech technology companies.He holds a Bachelors degree in Biochemistry from the University of Vermont as well as a Masters in Business Administration from Boston University. "Jerry has an exceptional track record in growing commercialization and customer adoption programs for some of today's leading technology platforms
  ...
  "Jerry is yet another central asset for VisEn as we drive our growth into this new era of molecular imaging in healthcare." "With its clearly leading technology platforms, deep research and development competencies, and industry-central partnerships, VisEn is truly expanding the opportunities and applications in molecular imaging today," commented Mr. Williamson.

• 
  www.genetix.co.uk/xhtml/news_story.aspx?titleid=156&pag - [Cached Version]
  Published on: 1/28/2008    Last Visited: 5/19/2008  

  clinical diagnostics industries, announces the appointment of Jerry Williamsonas President of U.S. Operations with immediate effect.
  
  In this newly-created position, Mr Williamson is responsible for leadingGenetix' commercial operations, servicing clients within the life sciences anddiagnostics part of the business and increasing the Company's focus on the U.S.marketplace.In addition to his commercial leadership responsibilities, MrWilliamson will also serve as Genetix' Global Leader of Diagnostic BusinessDevelopment, responsible for establishing and executing the Company's growthstrategy in the diagnostic and biomarker imaging markets.
  
  Mr Williamson has over 20 years of experience developing businesses within thebioscience technology marketplace.As president of Biacore, Inc., thepublicly-held analytical instrument company, he helped to drive company growthand also facilitated the post-acquisition integration with GE Healthcare LifeSciences.Prior to Biacore, Mr Williamson was President of Pyrosequencing,Inc., a European-owned public genomics company.Mr Williamson has also heldcommercial management positions at Genzyme Genetics and Roche Laboratories.
  ...
  Jerry will be a tremendous asset to the Genetix team.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 7/11/2007    Last Visited: 7/13/2007  

  our programs there," said Jerry Williamson, Chief Commercial Officer for VisEn.

• 
  www.sudburyminingsolutions.com/articles/Exploration/03- - [Cached Version]
  Last Visited: 8/18/2008  

  Other interesting opportunities come his way through a partner, Jerry Williamson, who works in the bush harvesting timber and building new logging roads.
  
  "If Jerry sees something he likes, we'll stake it."

• 
  2001 LPA Annual Meeting - [Cached Version]
  Published on: 11/6/2001    Last Visited: 4/5/2002  

  Jerry Williamson, Vice President, Global Diagnostic Business Unit, Pyrosequencing Inc.
  
  At each meeting LPA focuses on a new technology and its possible impact on the products and services provided by the LPA members.Molecular diagnostics is an emerging and fast growing area that could provide significant opportunities for many members.
  
  Building an Inspired Learning Organization

• 
  ALSSA - Industry News - [Cached Version]
  Published on: 3/11/2004    Last Visited: 2/14/2005  

  September 20, 2004 , Biacore International AB announces that Jerry Williamson has been appointed as the new President of Biacore Inc.Mr. Williamson will assume his new role immediately and will play a vital role in positioning Biacore,s U.S. sales organization to maximize the potential of the Company,s product offering in the world,s largest life science instrument market.Mr. Williamson takes over from Mr. Thomas P. Wida who is leaving the company.
  ...
  Mr. Williamson was until recently the President of Pyrosequencing Inc.Mr. Williamson joins Biacore from Beacon BioPartners, a strategic and business consultancy focused on the life science sector where he was the Managing Partner.
  
  Previously, on July 19, 2004.

• 
  BioExchange - Life Sciences and Biotechnology Resource... - [Cached Version]
  Published on: 11/5/2001    Last Visited: 11/21/2001  

  ``This collaboration represents the fifth molecular diagnostics partnership in just three months,'' said Jerry Williamson, VP and Molecular Diagnostics Business Head for Pyrosequencing AB. ``To work with leading clinicians at The Cleveland Clinic represents a terrific opportunity for us to apply our technology in the molecular diagnosis of important infectious diseases like tuberculosis.We're experiencing tremendous demand for Pyrosequencing technology from top medical institutions committed to developing clinically useful products for patients.''
  
  Pyrosequencing AB formed a Molecular Diagnostics Business Unit earlier this year to establish the Company's proprietary technology as a standard platform for clinical genetic analysis.Capitalizing on Pyrosequencing's worldwide market leadership in applied genetic analysis, the Molecular Diagnostics Business Unit is pursuing a global strategy to identify new diagnostic product opportunities, develop clinically useful molecular diagnostic assays, and collaborate with academic and commercial partners in the fields of disease diagnosis, clinical prognosis and pharmacogenomics.
  
  The Cleveland Clinic Foundation

• 
  Bioresearch Online News for bioresearch and life... - [Cached Version]
  Published on: 12/6/2001    Last Visited: 12/7/2001  

  "This collaboration is very timely and puts Pyrosequencing technology at the forefront of breakthrough research underway at UCSF in multiple sclerosis," said Jerry Williamson, VP and Molecular Diagnostics Business Head for Pyrosequencing AB."We are confident that our technology will accelerate this important research and that the results will provide the foundation for developing rapid diagnostic tests for MS."
  
  MS affects approximately one million people worldwide, with women being twice as likely as men to have the disease.At present, MS is incurable and the cause is unknown.The underlying problem may involve the inability of the body's immune system to distinguish "self" molecules from foreign molecules.

• 
  Diagnostic Tests for Oncology Developed Through... - [Cached Version]
  Published on: 12/17/2001    Last Visited: 12/17/2001  

  "Our collaboration with the Mayo Clinic is a great opportunity for us to apply our technology to the development of diagnostic tests in the field of oncology," said Jerry Williamson, VP and Molecular Diagnostics Business Head for Pyrosequencing AB."It also demonstrates the growing interest in our technology platform among leaders in the clinical diagnostic field.We expect to support the development of additional molecular diagnostics in areas where the accuracy, ease of use and cost efficiency of our technology is unparalleled."
  
  Pyrosequencing AB formed a Molecular Diagnostics Business Unit earlier this year to establish the Company's proprietary technology as a standard platform for clinical genetic analysis.Capitalizing on Pyrosequencing's worldwide market leadership in applied genetic analysis, the Molecular Diagnostics Business Unit is pursuing a global strategy to identify new diagnostic product opportunities, develop clinically useful molecular diagnostic assays, and collaborate with academic and commercial partners in the fields of disease diagnosis, clinical prognosis and pharmacogenomics.With this agreement, the Company has established eight important research collaborations to develop diagnostics in major diseases including infectious disease, cardiovascular disease, genetic disorders and hematology/oncology.

Page:  1 2 3 4